Cell Line Development Market worth $3.96 Billion by 2019


Posted March 29, 2018 by digitalmarket25

Cell Line Development Market is expected to reach $3.96 billion by 2019 from$2.2 billionin 2014, and is poised to grow at a CAGR of 12.5% from 2014 to 2019.

 
The “Cell Line Development Market by Product (Equipment, Media and Reagents), by Source, by type, by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019” analyzes and studies the major market drivers, threats, opportunities, and challenges.

Browse 114 market data tables and 64 figures spread through 225 pages and in-depth TOC on “Cell Line Development Market by Product (Equipment, Media and Reagents), by Source, by type, by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019”
http://www.marketsandmarkets.com/Market-Reports/cell-line-development-market-152900899.html
Early buyers will receive 10% customization on reports.
This report studies the global cell line development market for the forecast period of 2014 to 2019.This market is expected to reach $3.96 billion by 2019 from$2.2 billionin 2014, and is poised to grow at a CAGR of 12.5% from 2014 to 2019.
The global cell line development market is segmented on the basis of products, type of cell lines, source of cell lines, applications, and geographies.
Based on products, the cell line development market is categorized into equipment, and media &reagents.The media and reagents segment is expected to account for a major share of the cell line development market, by product in 2014.
The media and reagents segment is further divided into serum, media, and reagents.The reagents segment is expected to account for the largest share of the cell line development market in 2014.
The cell line development market, by type is further segmented into primary cell lines, continuous cell lines, hybridomas, and recombinant cell lines. Recombinant cell lines are expected to account for a major share of the cell line development market in 2014.
On the basis of source of cell lines, the market is segmented into mammalian, insect, and amphibian. The cell lines derived from mammalian source are likely to account for the largest share of the cell line development market in 2014.
Bioproduction, tissue engineering and regenerative medicine, toxicity testing, research, and drug discovery are the key application areas of cell lines. Bioproduction is expected to account for a major share among the application areas in the cell line development market.
On the basis of geography, the market is divided into North America, Europe, Asia, and Rest of the World (RoW). Rest of the World comprises of Latin America, Pacific countries, and Africa. North America holds the largest in the cell line development market, followed by Europe and Asia. However, the Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for cell line manufacturers.
Over the years, the demand for cell line development equipment and media and reagents is likely to increase owing to the increasing demand for monoclonal antibodies, rising vaccine production, and use of innovative technologies to develop cell lines. However, in spite of innovative technologies in the market, developing stable and authentic cell lines still remains a challenge. Increasing risk of pandemics and communicable diseases are expected to create opportunities for the development of cell lines.
Some of the major players in the global cell line development market include American Type Culture Collection (ATCC) (U.S.), Lonza Group AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), GE Healthcare (U.K.), Sigma-Aldrich Corporation (U.S.), Selexis SA (Switzerland), European Collection of Cell Cultures (ECACC) (U.K.), Corning, Inc. (U.S.), Wuxi App Tec, Inc. (China), and Sartorious AG (Germany).
About MarketsandMarkets
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: 1-888-600-6441
Email: [email protected]
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By digitalmarket
Phone 1-888-600-6441
Business Address MarketsandMarkets™,701 Pike Street Suite 2175, Seattle,
WA 98101, United States
Country United States
Categories Biotech , Health , Technology
Tags cell line development market
Last Updated March 29, 2018